- Analysts
- Dividend Payments
- Government Awards
- Insiders
- Lobbying Expenses
- Segment Revenues
- Shareholder Structure
- Supply / Portfolio
- Valuation Models [Soon]
- Board & Officers
- Business Intelligence
- Employee Voice
- ESG Scores [Soon]
- Mergers and Acquisitions
- Qualified Risks
- Clinical Trials [Soon]
- H1B/PERM Strategy
- Industry H&T [Soon]
- Macro
- News
- Patents / Trademarks [Soon]
- Peer Performance
- Relevant Disputes [Soon]
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that …
Shareholders
Major Shareholders · StructureBreakdown
The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. for Tenax Therapeutics, Inc.
Beneficial Owners Beta
Beneficial owners who control a significant portion of the shares outstanding.
Owner | Shares | Equivalence - $6.48 per share | Last Form/Filing | Last Transaction |
---|---|---|---|---|
10% Holder | ||||
Dellora Investments Lp
Uncategorized SEC Entity
|
View the form. Palmy doesn't track derivative holdings. | |||
Rich Stuart
Internal : Chief Medical Officer
|
0 | $0 | ||
Doogan Declan
Internal : Director
|
3,637,871 | $23,573,404.08 | ||
Officers/Directors Below 10% | ||||
Internal : Chief Medical Officer
|
662,517 | $4,293,110.16 |
A
662,517 x $0 =
$0
|
|
Internal : Director
|
1,667 | $10,802.16 |
P
1,666 x $0 =
$0
|
|
Internal : Director
|
0 | $0 |
|
|
Internal : CEO
|
0 | $0 |
|
|
Internal : Director
|
0 | $0 |
|
|
Internal : Director
|
0 | $0 |
|
|
Internal : Director
|
0 | $0 |
|
|
Internal : Interim CFO
|
0 | $0 |
|
|
Internal : Interim CFO
|
0 | $0 |
|
|
Internal : Interim CFO
|
0 | $0 |
|
|
Internal : CEO
|
0 | $0 |
|
|
Internal : Director
|
0 | $0 |
|
|
Internal : CFO
|
0 | $0 |
|
Shareholder Breakdown
The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public.
It's perfect to get a quick briefing regarding the shareholder structure of Tenax Therapeutics, Inc.
Short
We source Fail-To-Deliver data every month, directly from the SEC.